Digestive Diseases and Sciences

, Volume 53, Issue 5, pp 1370–1374 | Cite as

Serologic and Molecular Profile of Anti-HBc-Positive Blood Bank Donors in an Area of Low Endemicity for HBV

  • Carlos Kupski
  • Felipe R. Träsel
  • Felipe Mazzoleni
  • Marco A. Winckler
  • Ana Ligia Bender
  • Denise C. Machado
  • Virgínia M. Schmitt
Original Paper


Hepatitis B virus (HBV) infection leaves serological markers that indicate prior contact with the virus or an occult infection. The aim of this study was to determine the profile of HBV markers of individuals from a region of low HBV endemicity excluded from blood donation due to the presence of total anti-HBc antibodies but who tested negative for HBV surface antigen (HBsAg). The profile of 244 subjects exclusively anti-total hepatitis B core (anti-total HBc) reactive was determined. Markers such as anti-HBsAg, HBeAg (HBV core antigen) and anti-HBe (antibody to hepatitis Be antigen) were determined, and HB viral DNA (HBV-DNA) was identified by PCR analysis. Overall, 85.7% of the subjects had an anti-HBs (hepatitis B surface antigen antibody) titer higher than 10 IU/L; 154 samples were negative for HBeAg and 66.5% were reactive for anti-HBe. All samples were negative for HBV-DNA (n = 241). We found a significant association between the anti-HBe and anti-HBs titers (= 0.026). Most individuals from a low endemic area for HBV have shown anti-HBs titers that confer immunity against HBV, even though they were negative for HBV-DNA. In the light of a shortage of donated blood worldwide, we suggest that special measures should be considered that would facilitate the possible use of these rejected blood units in areas of low endemicity for HBV.


Blood donation HBV HBV-DNA Polymerase chain reaction  Serological markers 



This work was partially supported by Pontifícia Universidade Católica do Rio Grande do Sul and Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq.


  1. 1.
    Lee WM (1997) Hepatitis B virus infection. N Engl J Med 337:1733–1745PubMedCrossRefGoogle Scholar
  2. 2.
    Lin KW, Kirchner JT (2004) Hepatitis B. Am Fam Physician 69:75–82PubMedGoogle Scholar
  3. 3.
    Lok AS, McMahon BJ (2001) Chronic hepatitis B. Hepatology 34:1225–1241PubMedCrossRefGoogle Scholar
  4. 4.
    Zoulim F, Tong S, Trepo C (2004) Study of HBV replication capacity in relation to sequence variation in the precore and core promoter regions. Methods Mol Med 95:235–246PubMedGoogle Scholar
  5. 5.
    Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, Mares A et al (1990) The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 263:1218–1222PubMedCrossRefGoogle Scholar
  6. 6.
    Hoofnagle JH, Shafritz DA, Popper H (1987) Chronic type B hepatitis and the “healthy” HBsAg carrier state. Hepatology 7:758–763PubMedCrossRefGoogle Scholar
  7. 7.
    Silveira TR, da Fonseca JC, Rivera L, Fay OH, Tapia R, Santos JI, Urdeneta E et al (1999) Hepatitis B seroprevalence in Latin America. Rev Panam Salud Publica 6:378–383PubMedCrossRefGoogle Scholar
  8. 8.
    Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P (2001) Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology 34:194–203PubMedCrossRefGoogle Scholar
  9. 9.
    Draelos M, Morgan T, Schifman RB, Sampliner RE (1987) Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis B vaccination. JAMA 258:1193–1195PubMedCrossRefGoogle Scholar
  10. 10.
    Schifman RB, Rivers SL, Sampliner RE, Krammes JE (1993) Significance of isolated hepatitis B core antibody in blood donors. Arch Intern Med 153:2261–2266PubMedCrossRefGoogle Scholar
  11. 11.
    Kaneko S, Miller RH, Di Bisceglie AM, Feinstone SM, Hoofnagle JH, Purcell RH (1990) Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Application for clinical diagnosis. Gastroenterology 99:799–804PubMedGoogle Scholar
  12. 12.
    Malter JS, Gerber MA (1991) The polymerase chain reaction for hepatitis B virus DNA. Hepatology 13:188–190PubMedCrossRefGoogle Scholar
  13. 13.
    Reiche EM, Vogler IH, Morimoto HK, Bortoliero AL, Matsuo T, Yuahasi KK, Cancian SJ et al (2003) Evaluation of surrogate markers for human immunodeficiency virus infection among blood donors at the blood bank of “Hospital Universitario Regional Norte do Parana”, Londrina, PR, Brazil. Rev Inst Med Trop Sao Paulo 45:23–27PubMedGoogle Scholar
  14. 14.
    Mosley JW, Stevens CE, Aach RD, Hollinger FB, Mimms LT, Solomon LR, Barbosa LH et al (1995) Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 35:5–12PubMedCrossRefGoogle Scholar
  15. 15.
    Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP (2004) Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 44:1332–1339PubMedCrossRefGoogle Scholar
  16. 16.
    Sambrook JRD (2001) Preparation and analysis of eukaryotic genomic DNA. Molecular cloning – a laboratory manual, 3rd edn. Cold Spring Harbor Laboratory Press, New YorkGoogle Scholar
  17. 17.
    McMillan JS, Bowden DS, Angus PW, McCaughan GW, Locarnini SA (1996) Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology 24:1371–1378PubMedCrossRefGoogle Scholar
  18. 18.
    Sherlock S (1989) Virus hepatitis B, A, non-A, non-B. J Hepatol 8:254–258PubMedCrossRefGoogle Scholar
  19. 19.
    Zervou EK, Dalekos GN, Boumba DS, Tsianos EV (2001) Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece. Transfusion 41:652–658PubMedCrossRefGoogle Scholar
  20. 20.
    Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M et al (2002) Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 50:95–99PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Carlos Kupski
    • 1
    • 2
  • Felipe R. Träsel
    • 3
  • Felipe Mazzoleni
    • 1
  • Marco A. Winckler
    • 4
  • Ana Ligia Bender
    • 5
  • Denise C. Machado
    • 1
    • 3
  • Virgínia M. Schmitt
    • 3
    • 5
  1. 1.Department of Internal Medicine, Medical School/Hospital São LucasPontifícia Universidade Católica do Rio Grande do SulRio Grande do SulBrazil
  2. 2.Porto AlegreBrazil
  3. 3.Biomedical Research InstitutePontifícia Universidade Católica do Rio Grande do SulRio Grande do SulBrazil
  4. 4.Blood Bank of Hospital São LucasPontifícia Universidade Católica do Rio Grande do SulPorto AlegreBrazil
  5. 5.Faculty of PharmacyPontifícia Universidade Católica do Rio Grande do SulRio Grande do SulBrazil

Personalised recommendations